Sodium-glucose Cotransporter 2 inhibitor medications (SGLT2 inhibitors), which promote glucosuria, are known to raise the risk of urinary tract infection and candidiasis, risks that may be unacceptable in an immunocompromised population. Here, SLC5A2 is linked to candidiasis.